62,637
edits
Changes
no edit summary
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2019 || August 16 || Papillomavirus || Recommendation || "August 16, 2019 CDC published updated ACIP recommendations for human papillomavirus vaccination of adults."<ref>{{cite web |title=Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices |url=https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6832-H.pdf |website=cdc.gov |accessdate=1 June 2020}}</ref> || {{w|United States}}|-| 2019 || August 28 || Influenza || Recommendation || "CDC released ACIP recommendations on the use of influenza vaccines for the 2019–20 influenza season."<ref>{{cite web |title=Influenza ACIP Vaccine Recommendations |url=https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html |website=cdc.gov |accessdate=1 June 2020}}</ref> ||{{w|United States}}
|-
| 2019 || November 4 || Influenza || Vaccine approval || "FDA approved Fluzone High-Dose Quadrivalent (Sanofi Pasteur) for adults 65+ years of age—will be available for 2020–21 flu season."<ref>{{cite web |title=FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older |url=http://www.news.sanofi.us/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older |website=news.sanofi.us |accessdate=1 June 2020}}</ref> || {{w|United States}}
